Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

TP53 Y220C Mutation 1Prostate Cancer Patients 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Healthy Adult Participants 1Gastrointestinal Stromal Tumors 1Diabetes Mellitus, Type 2 1Advanced Solid Tumor 1Advanced Malignancies 1

Interventions

relacorilant 5Metformin 5Pioglitazone 4Dipeptidyl-Peptidase IV Inhibitors 4Sulfonylurea Compounds 3Sitagliptin Phosphate 3Resistance Training 3saxagliptin 2Vildagliptin 2Sodium-Glucose Transporter 2 Inhibitors 2Rosiglitazone 2Nutritional Status 2Glucagon-Like Peptide-1 Receptor Agonists 2Blood Specimen Collection 2voglibose 1somapacitan 1semaglutide 1repaglinide 1pembrolizumab 1miglitol 1metahexamide 1meglitinide 1mazdutide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1empagliflozin 1desaminopancreozymin octapeptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Type 2 × repaglinide × Clear all
NCT02475499 2016-03-14

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
886,172 enrolled
Gastrointestinal

Diabetes Mellitus, Type 2, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡